ADAPT NXT: Fixed Cycles or Every‐Other‐Week IV Efgartigimod in Generalized Myasthenia Gravis
Sign Up to like & getrecommendations! Published in 2025 at "Annals of Clinical and Translational Neurology"
DOI: 10.1002/acn3.70051
Abstract: This phase 3b, open‐label, randomized ADAPT NXT study investigated the efficacy, safety, and tolerability of efgartigimod administered in either a fixed cycles dosing regimen (3 cycles of 4 once‐weekly infusions, with 4 weeks between cycles) or a… read more here.
Keywords: cycles every; every week; nxt fixed; adapt nxt ... See more keywords
Enzyme replacement therapy in mucopolysaccharidosis type II with alternative dosing 1mg/kg idursulfase in every other week infusions
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Genetics and Metabolism"
DOI: 10.1016/j.ymgme.2018.12.180
Abstract: Enzyme replacement therapy for mucopolysaccharidosis II (MPS II) with Idursulfase (ElapraseR) has proven effective in reducing urinary glycosaminoglycan (uGAG) levels, liver and spleen volumes and in increasing walking distance. During phase II/III studies, 0.5mg/kg every… read more here.
Keywords: therapy; enzyme replacement; every week; week ... See more keywords
Anti-Adalimumab Antibodies in Patients with Noninfectious Uveitis Who Use Adalimumab Weekly or Every Other Week.
Sign Up to like & getrecommendations! Published in 2025 at "Ocular immunology and inflammation"
DOI: 10.1080/09273948.2025.2487164
Abstract: ABSTRACT Purpose Adalimumab (ADA) is the only biologic agent approved for treating non-infectious uveitis (NIU). Anti-drug antibodies (AAA) may be an essential factor associated with treatment failure. We conducted a study to determine the clinical… read more here.
Keywords: etiology; ada treatment; treatment; every week ... See more keywords
P533 Adalimumab 80mg every other week in inflammatory bowel disease: Treatment intensification outcomes in real life clinical practice
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab076.655
Abstract: Adalimumab (ADA) intensification is recommended for inadequate or loss of response in inflammatory bowel disease (IBD) patients. A new presentation of ADA 80mg administered every other week (eow) has been approved as an alternative to… read more here.
Keywords: treatment; intensification; 80mg eow; every week ... See more keywords
Reduction in skin and mucosal toxicity with pegylated liposomal doxorubicin utilizing every 2-week dosing.
Sign Up to like & getrecommendations! Published in 2019 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000000795
Abstract: Four ovarian cancer patients with severe plantar palmar erythrodysesthesia or mucositis precluding further therapy from pegylated liposomal doxorubicin on the standard every 4 week schedule were able to be treated on every 2-week schedule without… read more here.
Keywords: liposomal doxorubicin; skin mucosal; pegylated liposomal; every week ... See more keywords
Abstract 4440: Efficacy of Gen-1, an interleukin-12 immune gene therapy, at different dose frequencies
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4440
Abstract: Introduction: The purpose of this study was to investigate the effect of dosing frequency on the antitumor activity of intraperitoneal GEN-1, an interleukin-12 (IL-12) immune gene therapy in a mouse model of peritoneally disseminated ovarian… read more here.
Keywords: gen interleukin; every week; gen; interleukin immune ... See more keywords